Australia Relaxes Competition Rules To Facilitate Coronavirus Response
Generic And Brand Industry Bodies Team Up To Tackle COVID-19
Executive Summary
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
You may also be interested in...
Australian Industry Working To Minimize Medicines Shortages
Australia’s branded and generic drug industry associations have jointly raised concerns about the impact ongoing shortages could have on the country’s supply of medicines.
Covid-19: Australian Competition Body Confirms Industry Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.
Australian Body Confirms Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.